Janssen Global Services, LLC

Can the General Public Be a Proxy for an “At-Risk” Group in a Patient Preference Study? A Disease Prevention Example in Rheumatoid Arthritis (2024) DiSantostefano RL, Simons G, Englbrecht M, Humphreys JH, Bruce IN, Bywall KS, Radawski C, et al. Journal article Regulatory Issues of Platform Trials: Learnings from EU-PEARL (2024) Nguyen QL, Hees K, Hernandez Penna S, König F, Posch M, Bofill Roig M, Meyer EL, et al. Journal article, Review article Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study (2023) Schett G, Chen W, Gao S, Chakravarty SD, Shawi M, Lavie F, Zimmermann M, et al. Journal article Correction: Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study. (2023) Schett G, Chen W, Gao S, Chakravarty SD, Shawi M, Lavie F, Zimmermann M, et al. Journal article, Erratum Maximum Acceptable Risk Estimation Based on a Discrete Choice Experiment and a Probabilistic Threshold Technique (2023) Veldwijk J, DiSantostefano RL, Janssen E, Simons G, Englbrecht M, Schölin Bywall K, Radawski C, et al. Journal article Guselkumab, a Selective Interleukin-23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies (2023) Mcgonagle D, Mcinnes IBB, Deodhar A, Schett G, Shawi M, Chakravarty SDD, Kollmeier APP, et al. Journal article Acceptable risks of treatments to prevent rheumatoid arthritis among first-degree relatives: demographic and psychological predictors of risk tolerance (2022) Simons G, Janssen EM, Veldwijk J, Disantostefano RL, Englbrecht M, Radawski C, Valor-Mendez L, et al. Journal article MM-183 CARTITUDE-2 Cohort A: Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel) in Lenalidomide-Refractory Patients With Progressive Multiple Myeloma (MM) After 1–3 Prior Lines of Therapy (LOT) (2022) Hillengass J, Cohen AD, Delforge M, Einsele H, Goldschmidt H, Weisel K, Raab MS, et al. Journal article Exploring preferences of at-risk individuals for preventive treatments for rheumatoid arthritis (2022) Simons G, Bywall KS, Englbrecht M, Johansson EC, Disantostefano RL, Radawski C, Veldwijk J, et al. Journal article Preferences for preventive treatments for rheumatoid arthritis: discrete choice survey in the UK, Germany and Romania (2022) Simons G, Veldwijk J, Disantostefano RL, Englbrecht M, Radawski C, Bywall KS, Mendez LV, et al. Journal article